`
`SENJU EXHIBIT 2231
`INNOPHARMA v SENJU
`IPR2015-00903
`
`PAGE 1 OF 4
`
`
`
`PROLENSATM: Powered for penetration
`
`iMPORTANT R!SK iNFORMAT!GN ABOUT PROLENSA'''
`!31d!catim1s ~nd Us~ge
`
`PROL0328435
`
`PAGE 2 OF 4
`
`
`
`PROLENSATM: Powered for efficacy
`
`INflAMMATION CLEARANCE AT DAY 151•1
`
`Ctearance
`
`Complete
`clearance
`lJceiis.Ufl8re
`
`46%
`
`> 2x as many patients had
`complete clearance
`(P<0.0001)
`
`60
`50
`Percentage of patients
`
`70
`
`BO
`
`90
`
`Percentage of patients
`
`INFlAMMATION REDUCTION FDLWW!NG CATARACT SURGERY'
`
`Resolution
`
`of patients had zero
`to trace cells
`(P<0.0001)
`
`Iii'! PROLENSA'
`-:::;:;: Vehicle
`
`Iii PROLENSA'"
`;:;:;:; Vehicle
`
`0 .51 - - - - -
`
`0.0 ' - - - - - ' - - - - - ' - - - - - - - ' - - - - - - - ' - -
`Day I
`Day3
`Day8
`Day 15
`Days after cataract surgery
`
`Free
`
`Appmx!matety 4 of 5 patients were pain free at Day 11•29
`
`DESIGNED FOR COMFORT AND CONVENIENCE
`
`l!; More physiologic pHL'~>
`l!; Ocu!.ar comfort with converHent QD dosin~.; dernonstrated 1n PROLENS.A"'-treated eyes' 2
`
`Dosage and Administr~ti!Jil
`lnsn ens
`ntc the
`
`p R.O L "!'/._ ATM
`(bromfenac oohthalmic
`solution) 0.07%
`
`PROL0328436
`
`PAGE 3 OF 4
`
`
`
`PROlENSATM: Powered for penetration
`*' Advam:ed formulation f<lldW:<l!tes corneal penetration 1·>
`*' Powered for effkacy
`Pmverful clearance
`- tv1on:: than t.vvice as many patients ach:eved complete
`de;::Jrance vs vehicle at Day 1
`··· 80'Yo of patients had zero to trac;:; cdls2
`Rapid resolution
`··· Rapid reduction of inHamrnation following cataract surgery'
`
`Pain free at Day 1
`··· Approxirnately 4 of •:; patients were
`pain fn:;:; at O;::Jy F"
`*' Oesignad for ocular comfort <lind
`co1wenience with QD effic<llcy1,2
`
`iMPORTANT R!SK lNFDRMATiON ABOUT PROLENSA'"
`!ndic<!tionsand Usage
`
`Ot~s{Jge and Administration
`in::tillu:e
`
`postopera:;ve :nrtarn:n~;tcn &
`lir11lH'iii1r11°
`
`&
`
`fol U!i:i'.;~s:::iciil!'·J:OV
`Adverse Re{Jctions
`
`were
`
`PROLE' SATM
`(bromfenac ophthalmic
`solution) 0.07%
`
`PROL0328437
`
`PAGE 4 OF 4